Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC)
De La Pena, Lorena, Cortes, Javier, Manikhas, Alexey, Roman, Laslo, Semiglazov, Vladimir, Biakhov, Mikhail Yu, Dasappa, Lokanatha, Llombart, Antonio, Rozencweig, Marcel, Forenza, Salvatore, Goldfarb, Ronald H., Matera, Jeri, Azarnia, Nozar, Hudis, Clifford, Baselga, Jose
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC)
Moore, Malcolm J., Von Hoff, Daniel D., Ervin, Thomas J., Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey R., Hon, Jeremy K., Biakhov, Mikhail Yu, Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin D., Scheithauer, Werner, Ramanathan, Ramesh K., Tabernero, Josep, Goldstein, David, Wei, Xinyu, Romano, Alfredo
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article